Mobile website
Archive > Volume 30 Issue 5 > 2023,30(5):365-372. DOI:10.3872/j.issn.1007-385X.2023.05.001 Prev Next
Expert Forum
Targeted anti-tumor strategies based on the tumor-promoting mechanisms of B7H3: opportunities and challenges
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Immune checkpoint blockade (ICB) therapy, represented by PD-1/PD-L1 and CTLA-4, has achieved remarkable efficacy in the treatment of solid tumors; However, only less than 30% of the patients benefit from it, suggesting that there still exists other immune checkpoints molecule-mediated immunosuppression. B7H3 is a member of the B7 immunoglobulin superfamily. Unlike CTLA-4 or PD-1 which is mainly expressed in T cells to mediate their immunosuppression or depletion, B7H3 is not only inducibly expressed in immune cells, but also constitutively highly expressed in various tumor cells and tumor-associated vascular systems. B7H3 not only directly promotes the malignant biological phenotypes of tumor cells by activating multiple signaling pathways, but also indirectly promotes tumor progression, metastasis and drug resistance by remodeling tumor immunosuppressive microenvironment. Therefore, several targeted anti-tumor strategies targeting B7H3, including specific antibodies, antibody-drug conjugation (ADC) and CAR-T, have entered clinical trials and shown promising application prospects. However, in general, the research of B7H3 is still in the exploratory stage. There are still many bottlenecks and challenges to be overcome in the identification of reciprocal receptors, reduction of toxicity, breaking drug resistance, and optimization of combination drug therapy, etc.
Keywords:
Project Supported:
Clc Number:
